Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 18;1(1):21-23.
doi: 10.1016/j.medj.2020.12.004.

Vaccination Is the Only Acceptable Path to Herd Immunity

Angela L Rasmussen  1
Affiliations

Vaccination Is the Only Acceptable Path to Herd Immunity

Angela L Rasmussen. Med. .

Abstract

Population-level herd immunity is critical for long-term control of SARS-CoV-2. However, proposals to reach the herd immunity threshold through naturally acquired infection, rather than vaccination, have complicated public health efforts and popularized policies that will lead to widespread transmission and mortality. Vaccination is the only viable path to herd immunity.

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests

Figures

Figure 1
Figure 1
SARS-CoV-2 Spread in Populations with Different Susceptibility SARS-CoV-2 spread in a susceptible population (top panel) and in a population that has reached the herd immunity threshold (lower panel).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kulldorf M., Gupta S., Bhattacharya J. 2021. Great Barrington Declaration.https://gbdeclaration.org/
    1. Jones D., Helmreich S. A history of herd immunity. Lancet. 2020;396:810–811. - PMC - PubMed
    1. Anderson R.M., May R.M. Vaccination and herd immunity to infectious diseases. Nature. 1985;318:323–329. - PubMed
    1. Omer S.B., Yildirim I., Forman H.P. Herd immunity and implications for SARS-CoV-2 control. JAMA - JAMA. 2020 doi: 10.1001/jama.2020.20892. - DOI - PubMed
    1. Havers F.P., Reed C., Lim T., Montgomery J.M., Klena J.D., Hall A.J., Fry A.M., Cannon D.L., Chiang C.F., Gibbons A. Seroprevalence of antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May12, 2020. JAMA Intern. Med. 2020 doi: 10.1001/jamainternmed.2020.4130. - DOI - PubMed